Pericyte Insulin Receptors Modulate Retinal Vascular Remodeling and Endothelial Angiopoietin Signaling

Nele Warmke,1,2 Fiona Platt,1 Alexander F. Bruns,1 Claire H. Ozber,1 Natalie J. Haywood,1 Yilizila Abudushalamu,1 Charles Slater,1 Victoria Palin,1 Piruthivi Sukumar,1 Stephen B. Wheatcroft,1 Nadira Y. Yuldasheva,1 Mark T. Kearney,1 Kathryn J. Griffin,1,* and Richard M. Cubbon1,*

1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; and 2Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany

ORCID numbers: 0000-0002-6741-9012 (S. B. Wheatcroft); 0000-0001-7844-3600 (R. M. Cubbon); 0000-0002-3154-3273 (K. J. Griffin).

*Denotes equal contribution to senior authorship.

Abstract

Pericytes regulate vascular development, stability, and quiescence; their dysfunction contributes to diabetic retinopathy. To explore the role of insulin receptors in pericyte biology, we created pericyte insulin receptor knockout mice (PIRKO) by crossing PDGFRβ-Cre mice with insulin receptor (Insr) floxed mice. Their neonatal retinal vasculature exhibited perivenous hypervascularity with venular dilatation, plus increased angiogenic sprouting in superficial and deep layers. Pericyte coverage of capillaries was unaltered in perivenous and periarterial plexi, and no differences in vascular regression or endothelial proliferation were apparent. Isolated brain pericytes from PIRKO had decreased angiopoietin-1 mRNA, whereas retinal and lung angiopoietin-2 mRNA was increased. Endothelial phospho-Tie2 staining was diminished and FoxO1 was more frequently nuclear localized in the perivenous plexus of PIRKO, in keeping with reduced angiopoietin-Tie2 signaling. Silencing of Insr in human brain pericytes led to reduced insulin-stimulated angiopoietin-1 secretion, and conditioned media from these cells was less able to induce Tie2 phosphorylation in human endothelial cells. Hence, insulin signaling in pericytes promotes angiopoietin-1 secretion and endothelial Tie2 signaling and perturbation of this leads to excessive vascular sprouting and venous plexus abnormalities. This phenotype mimics elements of diabetic retinopathy, and future work should evaluate pericyte insulin signaling in this disease.
Pericytes are an integral component of the microvasculature, and are required for the stabilization and quiescence of the capillary endothelial cells they interact with (1). Newly forming angiogenic sprouts attract pericytes by secreting growth factors, such as platelet derived growth factor-β (PDGF-B) (2). Their presence prevents endothelial hyperproliferation and sprouting in growth factor–abundant environments, but also facilitates endothelial survival as growth factor abundance subsides, impacting on many facets of vascular biology (1, 2). They achieve this by closely wrapping around capillary endothelial cells, influencing their biology via direct interactions and paracrine signaling (2). The critical role of pericytes is exemplified by the embryonic lethality of PDGF-B knockout mice (3), which lose >95% of pericytes and exhibit highly abnormal vascular development and hemorrhage. Recent data from Pdgfrb<sub>ret/ret</sub> mice, which lose 70% to 80% of pericytes, reveal excessive angiogenic sprouting and a venous-shifted phenotype of endothelial cells, together with excessive endothelial expression of angiopoietin-2 (ANGPT2), a factor involved in angiogenic sprouting and vascular patterning (4). Attrition of pericytes occurs early in the natural history of diabetic microvascular disease, and is most widely appreciated in the retina, where it promotes features including venous dilation, hemorrhage, and excessive angiogenesis (5-7). Vascular endothelial insulin resistance is a key feature of diabetic vascular disease and is an important contributor to endothelial dysfunction (8). Notably, insulin receptor expression is comparable in pericytes and microvascular endothelial cells (9), and in vitro studies have shown greater proliferative responses to insulin in pericytes vs endothelial cells (10). However, the role of pericyte insulin signaling in vivo remains entirely unexplored and we set out to understand this in the context of developmental angiogenesis.

**Research Design and Methods**

**Mouse Models and Husbandry**

In order to knockout the insulin receptor in pericytes, mice with loxP sites flanking exon 4 of the Insr gene (referred to as floxed insulin receptor) (11) were crossed with mice expressing Cre-recombinase under control of the Pdgfrb promoter (referred to as Pdgfrb-Cre mice) (12). Their progeny were crossed to generate mice with homozygous deletion of the insulin receptor in Pdgfrb-expressing cells (ie, Pdgfrb-Cre.Insr<sub>loxp/loxp</sub>, referred to as PIRKO mice); these were always compared with Cre-negative Insr<sub>loxp/loxp</sub> littermate controls. In order to define the spatial activity of Pdgfrb-Cre, these mice were separately crossed with mTmG reporter mice (13), in which the presence of active Cre modifies the mTmG reporter transgene from expression of membrane-targeted tandem Tomato to enhanced green fluorescent protein (eGFP). Founding insulin receptor floxed mice (strain 6955) and mTmG mice (strain 7576) were purchased from Jackson Laboratories (Farmington, CT, USA), while Pdgfrb-Cre mice were purchased from Taconic Biosciences (Germantown, NY, USA). All experimental mice were kept in a conventional animal facility with a 12-hour light/dark cycle and received a standard chow diet. Genotyping was performed by Transnetyx Inc. (Cordova, TN, USA) using real-time polymerase chain reaction (PCR) of ear notch genomic DNA. All procedures were approved by the Animal Welfare and Ethical Review Committee at the University of Leeds and were conducted in accordance with The Animals (Scientific Procedures) Act of 1986 Amendment Regulations 2012 (SI 2012/3039) under United Kingdom Home Office project licenses PL40/3523 and P144DD0D6.

**Assessment of Retinal Vasculature**

Retinal angiogenesis was studied at P5, P10, and P15. For each experiment, mice from 3 litters were used to account for intrauterine and interindividual variability. Eyes were dissected and placed in 4% paraformaldehyde; retinas were then dissected, permeabilized, blocked and stained according to the method of Pitulescu et al. (14). Immunostaining was performed using primary antibodies against NG2 (15), Collagen IV (16), FoxO1 (17), DLL4 (18), EphB4 (19), COUP-TFII (20), and phosphoTie2 (21), and secondary antibodies against rabbit (Alexa Fluor 488) or goat (Alexa Fluor 568) (23). Proliferation by EdU-incorporation was detected with a Click-iT EdU Alexa Fluor 647 Imaging Kit (Invitrogen C10340). Retinal vasculature was labeled with isolectin B4 conjugated to Alexa Fluor 487 (22) or goat (Alexa Fluor 568) (23). Proliferation by EdU-incorporation was detected with a Click-iT EdU Alexa Fluor 647 Imaging Kit (Invitrogen C10340). Retinal vasculature was labeled with isolectin B4 conjugated to Alexa Fluor 488 or 647, and nuclei were labeled with Hoechst 33342. Retinas were flat mounted with ProLong Gold Antifade Mountant (Invitrogen P36930) and imaged using confocal microscopy (Zeiss LSM880) using FIJI (NIH, Bethesda, MD) for all analyses.

For retinal radial outgrowth, vascularity, and branchpoint analysis, whole-retina tile-scan images were collected at 10× magnification using z-stacking and maximum intensity projection. Radial outgrowth was measured as distance between the optic disk and the angiogenic front. For vascularity and number of branchpoints, the vascular plexus was divided into central and peripheral zones.
bounded at one-third of the distance between the optic disk and the angiogenic front; in some analyses, the periphery was subdivided into arterial and venous regions (Fig. 1). Vascularity of the deeper plexus in P10 retinas was quantified as ratio of vascularized area of the deeper plexus and vascularized area of the fully outgrown superficial plexus. Vascular plexus branchpoints were defined in 5 to 8 (200 μm)² regions of interest in each retina, located between arteries and veins. Sprouting angiogenesis by active tip cells was imaged at 40× magnification in 6 to 8 regions at the vascular front between arteries and veins using z-stacking and maximum intensity projection; the number of sprouts was quantified per mm of vascular front.

Pericyte coverage by NG2 staining was imaged at 20× magnification and coverage was determined by thresholding pericyte NG2 signal over vascular isolectin B4 signal. In each retina 2 or 3 images of regions containing artery, vein, and capillary plexus were collected using tile-scanning, z-stacking, and maximum intensity projection. For quantifying vessel regression and proliferation by 5-ethynyl-2′-deoxyuridine (EdU) incorporation, 3 or 4 retina segments were imaged at 20× magnification, using tile scanning. Empty collagen IV, sleeves were identified as collagen IV structures between established vessels, but without overlaid isolectin B4 staining. The total number of EdU-positive nuclei were counted per segment. The number of regressed vessels or proliferating nuclei was then normalized per mm² vascular area. FoxO1 nuclear localization was assessed by FoxO1/Hoechst colocalization inside the isolectin B4–stained vascular plexus. Three or 4 images of the arterial and venous regions were collected at 40× magnification, using z-stacking and maximum intensity projection. The number of vascular FoxO1-positive nuclei over all vascular nuclei was analyzed in a (150 μm)² region of interest adjacent to an artery or a vein. Tie2 activation was analyzed by mean staining intensity in artery, arterial plexus, venous plexus, and vein, and corrected for mean staining intensity in artery. In each retina, 2 or 3 images were collected at 40× magnification. Images had to contain an artery, vein, and the capillary plexus using tile-scanning, z-stacking, and maximum intensity projection. High background staining required processing of the images by removing bright outliers (antibody precipitates) and background subtraction. The isolectin B4 signal was used to create a mask and to remove any Tie2 signal from outside the vasculature. Mean staining intensity was measured across an individual vessel and 3 measurements were taken per region.

**Isolation and Culture of Murine Pericytes**

Pericytes were isolated from the brains of adult mice (8-10 weeks of age), adapting the method of Tigges et al. (24). Brain tissue, collected after cervical dislocation, was manually minced and digested in 1 mg/mL collagenase/dispase (Roche 11097113001) on a MACSmix Tube Rotator (Miltenyi Biotec) at 37°C for 45 to 60 minutes. Myelin was removed by centrifugation after resuspension of the brain pellet in Dulbecco’s modified Eagle’s medium with 20% bovine serum albumin (BSA). Cell pellets were then cultured at 37°C in 5% CO₂ on 2% gelatin-coated plates using Endothelial Cell Growth Medium MV2 (PromoCell C-22022, supplemented with an additional 10% fetal bovine serum and 1% antibiotic-antimycotic solution (Sigma-Aldrich A5955)). Upon confluence, cells were trypsinized with 0.25% Trypsin-EDTA (Thermofisher 2520056) and transferred into a new culture vessel with subsequent culture in Pericyte Medium (ScienCell 1201) until passage 5. To confirm the phenotype with immunostaining, cells were fixed in 4% paraformaldehyde, and permeabilized and blocked in 0.25% PBS-Triton-X100 supplemented with 1% BSA and 5% goat serum. Cells were incubated overnight in antibodies against NG2 (15), or VEGFR2 as an endothelial marker (25). Cells were then incubated with a fluorescent antirabbit secondary antibody (22), followed by nuclear counterstaining with Hoechst 33342. Confocal microscopy was performed (Zeiss LSM880) at 40× magnification.

**Culture of Human Pericytes and Endothelial Cells**

Commercially available human brain pericytes (HBPCs) were purchased from ScienCell and cultured in pericyte
medium (ScienCell 1200 and 1201). Experiments were performed at passage 4 to 8. HBPCs were transduced using short hairpin RNA (shRNA) lentivirus particles, at a concentration of 15 multiplicity of infection, against the insulin receptor (Sigma-Aldrich SHCLNV-NM000208/TRCN0000196786) or against green-fluorescent protein (Sigma-Aldrich SHC002H) to create shIR and control HBPCs, respectively. To assess ANGPT1 secretion in shIR and control HBPCs, conditioning was performed for 24 hours in M199 basal media (Sigma-Aldrich M4530) supplemented with 2% fetal bovine serum, 1% pericyte growth supplement (ScienCell 1252), and 100 nM insulin. ANGPT1 concentration in human pericyte conditioned medium was quantified using the Quantikine Human Angiopoietin-1 ELISA (26). Conditioned medium from shIR and control HBPCs was also applied to human umbilical vein endothelial cells (HUVECs; PromoCell 12200) to assess Tie2 activation. HUVECs were serum-deprived in M199 basal media for 2 hours and conditioned medium was applied for 15 minutes before collecting cell lysates for immunoblotting.

**Quantitative Polymerase Chain Reaction**

Total RNA was isolated using TRI Reagent Solution (Thermo Fisher Scientific). For tissue RNA extraction, tissue was homogenized in TRI Reagent using a Qiagen TissueLyser at 25 Hz. Phase separation was performed with 1-bromo-3-chloropropane and the RNA-containing upper phase was collected. By adding isopropanol, RNA was precipitated at 25°C. Phase separation was performed with 1-bromo-3-chloropropane and the RNA-containing upper phase was collected. By adding isopropanol, RNA was precipitated and the RNA pellet was washed with 99.5% ethanol. RNA was dissolved in DNase/RNase free water and quantified by using a DeNovix DS-11 FX + spectrophotometer. Reverse transcription was performed using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific 4387406). For quantitative PCR, PrecisionPLUS qPCR Master Mix (Primer Design PPLUS-CL) and the following 6-carboxyfluorescein (FAM) labeled TaqMan probes were used: mouse instr (Mm00439688_m1); mouse actb (Mm02619580_g1); mouse angpt1 (Mm00456503_m1); mouse angpt2 (Mm00545822_m1), mouse hes1 (Mm01342805_m1), mouse bey1 (Mm00468865_m1), and mouse nrarp (Mm00482529_s1). Amplification of gene fragments was assessed using a Roche LightCycler 480.

**Immunoblotting**

Protein concentrations in cell lysates were quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Protein was separated by denaturing gel electrophoresis on NuPAGE 4-12% Bis-Tris Protein Gels using NuPAGE MES SDS running buffer. Protein was transferred onto PVDF membranes using a Trans-Blot Turbo Transfer System. Membranes were blocked in blocking buffer (tris-buffered saline with 0.1% Tween-20 (TBS-T 0.1%, 50 mM Tris, 150 mM NaCl at pH 7.6, 0.1% Tween-20 supplemented with 5% BSA in PBS) before overnight incubation in primary antibodies against HSP90 (27), beta-actin (28), phosphoTie2 (21), or insulin receptor beta subunit (29), diluted in blocking buffer at 4°C. Washes in 0.02% TBS-T were performed before incubation with a secondary antibody against mouse (30), or rabbit (31), diluted in blocking buffer or 0.02% TBS-T for 2 hours at room temperature. Membranes were imaged with a Syngene G:BOX after incubation with Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore).

**Statistics and Measures to Reduce Measurement Bias**

Statistical analysis was performed using GraphPad Prism 7. Data are presented as mean ± standard error of the mean (SEM) and results are considered significant when P ≤ .05. Where appropriate, an unpaired or paired t-test has been performed; when distributions were heterogeneous in variability, a Welch-t-test was performed instead. Analysis of 2 independent factors on 1 dependent variable was performed by a 2-way analysis of variance (ANOVA). In order to reduce measurement bias, all experiments were performed and analyzed by investigators blinded to genotype or treatment allocation until experiments were completed.

**Results**

**PIRKO Exhibit Retinal Venous Plexus Hypervascularity**

In order to define the spatial activity of Pdgfrb-Cre, these mice were crossed with mTmG reporter mice (13), in which the presence of active Cre modifies the mTmG reporter transgene from expression of membrane-targeted tandem Tomato to eGFP. Examination of the P5 retina confirmed appropriate vascular development, with eGFP expression colocalizing only with immunostaining for the mural cell marker NG2 (Fig. 2A). Next, Pdgfrb-Cre mice were crossed with insulin receptor floxed mice to generate mice with homozygous deletion of the insulin receptor in Pdgfrb expressing cells (now referred to as PIRKO); these were always compared with Cre-negative Insrlox/lox littermate controls. PIRKO were born at expected frequencies, exhibited no gross developmental abnormalities and had comparable weight to littermate controls (Fig. 2B). Isolation and culture of brain pericytes from PIRKO...
Figure 2. Confirmation of appropriate pericyte insulin receptor knockout. (A) Cre-recombination was assessed in PDGFRβ-Cre<em>EmG<sup>+</sup></em>-/− mice. Endogenous eGFP expression colocalizes with pericyte NG2 expression in P5 retinas. The vasculature was labeled with isoelectin B4 (gray). (B) There is no difference in body weight at P5 between PIRKO and control. (C) Brain pericytes were isolated from adult control and PIRKO mice. Knockdown of the insulin receptor was confirmed on RNA level (relative to β-actin). (D) Isolated brain pericytes at passage 5 express the pericyte marker NG2 (central panel), but not the endothelial marker VEGFR2 (right panel), scale bar 50 µm. (E) Insulin receptor protein level in reduced in isolated brain pericytes from PIRKO. (F) PDGFRβ-targeted insulin receptor knockdown does not affect whole tissue insulin receptor expression in P5 retinas and (G) P5 lungs. Data presented as mean ± SEM, unpaired t-test, *<i>P</i> < .05, **<i>P</i> < .01, n = 6, 6 (C), n = 9, 9 (E), n = 7, 7 (F,G).
revealed these to express appropriate pericyte markers and exhibit approximately 90% reduction in \textit{Insr} mRNA (Fig. 2C and 2D); moreover, these had a 50% reduction in insulin receptor protein, with apparent truncation of expressed protein based on reduced molecular mass (Fig. 2E). Notably, insulin receptor protein was not reduced in whole retinal or lung lysates from P5 PIRKO mice (Fig. 2F and 2G). In 8-week-old mice, fasting serum glucose was comparable in PIRKO mice and wildtype littermates, although fasting serum insulin was greater in PIRKO (Fig. 3A and 3B).

Retinal vascular development was defined by staining P5 retinal wholemounts with isolectin B4, which highlights vascular endothelium (Fig. 4A). Radial outgrowth of the emerging plexus was comparable in PIRKO and control littermates (Fig. 4B), although PIRKO exhibited increased branching complexity in the peripheral half of the plexus (Fig. 4C). We noted increased vascularity in the regions adjacent to retinal veins and quantified this as vascular density (the proportion of retinal area covered by vasculature) separately in the perivenous and arterial plexi. Although no difference was noted between PIRKO and control littermates in arterial plexus vascular density, this was clearly increased in the venous plexus of PIRKO (Fig. 4D). Using higher magnification images of the emerging vascular front (Fig. 4E), we also defined the number of sprouting tip cells, normalized to the perimeter of the vascular front, and found this to be increased in PIRKO (Fig. 4F).

In order to better understand the retinal venous plexus abnormalities of PIRKO, we then conducted additional analyses at P5, P10, and P15 (Fig. 5A). These revealed that the perivenous hypervascularity diminished with time, although was still evident at P10. Beyond increased venous plexus area, we also noted increased retinal vein diameter in P5 and P10 PIRKO mice, with a nonsignificant increase evident at P15 (Fig. 5B and 5C). At P10, we also studied the deep vascular plexus, which sprouts from the primordial superficial layer, and found significantly increased vascular area in PIRKO mice (Fig. 6A and 6B). In summary, these data suggest PIRKO have increased vascular sprouting and abnormal venous plexus development in early postnatal life.

Since hypervascularity could be explained by diminished vascular regression (ie, pruning of unnecessary vessels, which is essential for normal vascular development), we stained retinas for collagen IV (Fig. 7A); empty collagen IV sleeves without overlying isolectin B4 staining provide evidence of recent vascular regression. We observed no difference in the number of these events per area of retinal vasculature (Fig. 7B). Excessive proliferation of endothelial cells could also contribute to hypervascularity and so we injected P5 pups with EdU, a nucleoside analogue that incorporates into newly forming DNA, allowing fluorescent labeling of proliferating cell nuclei (Fig. 7C). Again, we saw no difference in the number of EdU staining endothelial (isolectin B4 stained) nuclei, normalized to retinal vascular area, in PIRKO mice vs littermate controls (Fig. 7D).

Another potential explanation for abnormal venous plexus development is abnormal arteriovenous patterning and so we stained retinas with Dll4 (enriched in arteries), EphB4, and Coup-TFII (both enriched in veins), yet these revealed appropriate staining patterns in PIRKO (Fig. 8A-8C). Since Notch signaling is implicated in vascular patterning and development, we also performed qPCR for canonical Notch targets (\textit{Hes1, Hey1, Nrarp}) in whole retinal tissue, although no differences were observed (Fig. 8D). Given our focus on pericytes, we also stained retinas for NG2 in order to define mural cell coverage of the vasculature. The area of retinal arteries, veins and capillary plexi covered with NG2 staining was comparable in PIRKO mice, vs littermate controls, at P5, P10, and P15 (Fig. 9A-9F).

Staining for the vascular smooth muscle marker alpha-smooth muscle actin also revealed no differences at P5, with coverage appropriately restricted to developing retinal arteries (Fig. 9G).

**Angiopoietin-1 Signaling Is Reduced in PIRKO**

The altered retinal endothelial biology of PIRKO mice led us to explore other known mechanisms of pericyte–endothelial communication that can influence venous development. Angiopoietins are a family of ligands that profoundly alter endothelial biology, acting via endothelial Tie2 receptors that signal downstream via Akt and the transcription factor FoxO1 (32). Tie2, Akt, and FoxO1 have all been implicated in venous development (33-36). Pericytes secrete Angiopoietin-1, an agonist of Tie2, encoded by the \textit{Angpt1} gene. We observed that \textit{Angpt1} mRNA was decreased in...
cultured brain pericytes from PIRKO (Fig. 10A). In order to explore the relevance of this in vivo, we then stained retinas for activated Tie2 receptors, using its phosphorylation at Y1102 as a proxy of activation. In spite of similar absolute staining intensity in retinal arteries (Fig. 10B), we noted a pronounced reduction in perivenous capillary plexus Tie2 phosphorylation, normalized to arterial signal in each image (Fig. 10C and 10D). Since downstream signaling via Akt to FoxO1 is thought to be important in Tie2-mediated venous patterning, we stained retinas for FoxO1 (Fig. 10E), taking advantage of the fact that diminished Tie2/Akt signaling should increase nuclear localization of FoxO1. In support of reduced perivenous Tie2 signaling, we found endothelial nuclear localization of FoxO1 was increased in perivenous regions of PIRKO, vs littermate controls, with no difference in periarterial regions (Fig. 10F). Importantly, endothelial FoxO1 activity induces expression of angiopoietin-2 (a context-specific antagonist of ANGPT1, expressed predominantly by endothelial cells, encoded by the gene Angpt2) and we observed increased Angpt2 mRNA in PIRKO retinas and lung (Fig. 10G and 10H). Hence, PIRKO mice have reduced perivenous Tie2 signaling, associated with reduced pericyte expression of its agonist ANGPT1, and increased expression of its antagonist ANGPT2; collectively, these would be expected to promote venous development.
Insr Knockdown in Human Brain Pericytes Recapitulates Abnormal Angiopoietin Signaling

Finally, we asked whether these data are relevant to human pericyte biology, and so knocked down the insulin receptor in human brain pericytes using lentiviral transduction of Insr shRNA (shIR) vs control GFP-targeting shRNA (shCtrl). This achieved approximately 25% reduction in insulin receptor protein (Fig. 11A). We then quantified secreted angiopoietin-1 protein in conditioned medium from these pericytes and found that Insr knockdown reduced ANGPT1 concentrations (Fig. 11B), in keeping with data from cultured PIRKO pericytes. To establish whether this was functionally relevant for venous endothelial cells, we then exposed HUVECs to conditioned medium for 15 minutes before lysing cells for phospho-Tie2 immunoblotting. This revealed that conditioned medium from Insr knockdown pericytes was significantly less able to activate Tie2 in HUVECs.
(Fig. 11C and 11D), supporting our hypothesis that insulin signaling in pericytes regulates pericyte to endothelial cell communication via endothelial Tie2 signaling (Fig. 12).

**Discussion**

Our work provides the first ever in vivo assessment of pericyte insulin receptor function and points to its fundamental role in vascular quiescence and patterning. Specifically, we show that pericyte insulin receptors suppress vascular sprouting and influence venous plexus patterning during developmental angiogenesis, and link this with regulation of paracrine angiopoietin signaling. While we have not studied pathological angiogenesis, our data may be relevant to disease states associated with altered insulin receptor biology, such as diabetic retinopathy, and future work should address this possibility and its translational potential.

**Pericytes, Angiopoietins, and Vascular Biology**

The essential role of pericytes during vascular development has already been alluded to, based upon the embryonic lethality and highly abnormal vascular development of PDGF-B knockout mice (3), which lose >95% of pericytes. Pdgfb<sup>ret/ret</sup> mice, which lose 70% to 80% of pericytes, survive into adulthood and exhibit excessive angiogenic sprouting with venous-shifted phenotype of endothelial cells, together with excessive endothelial expression of ANGPT2 (4). Although their phenotype is more extreme and sustained than PIRKO, there are clear parallels in terms of vascular morphology and altered angiopoietin expression. However, we did not observe a reduction in pericyte coverage associated with these structural and molecular abnormalities, suggesting instead that pericyte function is altered. While this dysfunction is likely to encompass more than just reduced ANGPT1 secretion, we were able to elicit diminished paracrine ANGPT1 signaling in venous plexus endothelial cells,
evidenced by: reduced Tie2 phosphorylation; increased nuclear FoxO1 localization; and increased Angpt2 mRNA (likely resulting in further reduction in ANGPT1 signaling due to its antagonistic role). ANGPT1 secreted by pericytes signals via endothelial Tie2 receptors (37), resulting in potent activation of the kinase Akt, which in turn phosphorylates the transcription factor FoxO1 (32), directing it to a cytoplasmic location; among many other effects, this represses Angpt2 expression (32). Importantly, diminished endothelial signaling at either Tie2, Akt, or FoxO1 axis is consistently associated with abnormal venous patterning (33-36). Hence, the venous plexus hypervascularity we observed is consistent with the molecular perturbations we describe. Moreover, the
increased vascular sprouting of PIRKO is consistent with their increased expression of ANGPT2, given that this has an important role in sprouting angiogenesis (2, 38). It would be interesting to explore ANGPT2 secretion by human endothelial cells exposed to conditioned medium from insulin resistant pericytes and future studies should address this. However, it should be noted that angiopoietin signaling is complex, with Tie2 expression and angiopoietin responsiveness also being evident in pericytes (39, 40), and our findings should be considered in this context. Moreover, angiopoietins are part of a much broader angiogenic regulatory network, and it is particularly important to consider their interaction with vascular endothelial growth factor (VEGF), the principal angiogenesis stimulating growth factor. While we did not define VEGF bioactivity in the retina of PIRKO mice, the work of Park et al. illustrates that loss of pericytes is associated with a much more pronounced phenotype (mimicking diabetic retinopathy) in the presence of increased VEGF (41). Park and colleagues also confirm that endothelial FoxO1, but not pericyte-derived ANGPT1, contributes to the vascular dysfunction caused by pericyte loss, suggesting other pericyte derived factors are important (41). Our recent work has also shown interactions between endothelial insulin receptors and VEGF signaling in endothelial cells during angiogenesis,
illustrating a broader role of insulin signaling in vascular remodeling (42). Hence, insulin signaling appears to play a complex role in angiogenesis, and further work will be required to address the uncertainties described above.

Diabetic Microvascular Disease and Pericytes

Diabetes dysregulates many essential endothelial–pericyte signaling mechanisms (39, 43-46). Moreover, there is good evidence that diabetes reduces the abundance and
Figure 10. Angiopoietin/Tie2 signaling is altered in PIRKO. (A) Angpt1 mRNA expression is reduced in isolated brain pericytes from PIRKO compared with control. (B) and (C) Phosphorylation of Tie2 was assessed in P5 retinal territories (C), and normalized to the mean staining intensity of pTie2 in arteries (B), scale bar 50 µm. (D) pTie2 staining is reduced in the venous plexus PIRKO. (E) P5 retinas were stained against FoxO1 and nuclear FoxO1 localization was assessed by FoxO1/Hoechst colocalization. FoxO1 positive nuclei are labeled with an arrow, scale bar 50 µm. (F) Nuclear FoxO1 in the arterial plexus is similar in both groups, whereas nuclear FoxO1 localization is increased in the venous plexus in PIRKO compared to control. (G) Angpt2 mRNA expression (relative to β-actin) is increased in P5 retinas and (H) P5 lungs in PIRKO compared to control. Data presented as mean ± SEM, unpaired t-test (A, B, F, G, and H), or 2-way ANOVA with Sidak’s multiple comparison test (D), *P < .05, ***P < .001, n = 6, 6 (A), n = 10, 10 (B, D) n = 7, 10 (F) n = 7, 7 (G, H); A, artery; V, vein.
Figure 11. Pericyte conditioned medium activates the Tie2/Akt signaling axis in HUVECs. Knockdown in human brain pericytes was performed using short hairpin RNA transduction particles against the insulin receptor (shIR) or green-fluorescent protein (shCtrl). (A) Knockdown efficiency with a multiplicity of infection of 15 results in a minor reduction of insulin receptor expression on protein level in shIR. (B) Secretion of Angpt1 into cell culture supernatant is reduced in shIR compared to shCtrl after 24 hours, upon stimulation with 100 nM insulin. (C) HUVECs were treated with serum-free cell-starvation medium (SFM), basal medium (BM) used for conditioning, or shCtrl or shIR conditioned medium (CM), either collected under untreated or 100 nM insulin-stimulated conditions, for 15 minutes to assess activation of the Tie2/Akt signaling axis. (D) Tie2 activation in HUVECs treated with conditioned medium from 100nM insulin-stimulated shIR is reduced compared to shCtrl. Data presented as mean ± SEM, paired t-test (used because within each experimental replicate, shIR or shCtrl were transduced in pericytes derived from a single donor). *P < .05, n = 9, 9 (A, D) and n = 5, 5 (B).
alters the function of retinal pericytes; this is thought to promote diabetic retinopathy, characterized by early vasoregression, followed by exaggerated regeneration of friable leaky neovessels (39, 44). Importantly, venous dilatation is a defining characteristic of early diabetic retinopathy that correlates with microvascular disease in other organs (7, 47), and is even apparent in prediabetes (6). While the impact in other vascular beds is not well studied (5), electron microscopy of human skeletal muscle suggests diabetes produces similar attrition (46, 48), but the consequences are unknown. Notably, diabetic retinopathy is phenocopied by retinal ANGPT2 overexpression (38), whilst ANGPT1 overexpression can retard the development of diabetic retinopathy and nephropathy (49, 50). It has also been reported that topical application of insulin aids diabetic wound healing and neovascular maturation in an ANGPT1-dependent manner (51). Hence, pericyte dysfunction and altered angiopoietin biology are key drivers of diabetic microvascular disease. However, it remains unclear whether insulin receptor expression or downstream signaling is altered in pericytes in the context of diabetes, and this warrants careful exploration in future studies.

**Limitations**

While our work has important strengths, described above, it is important to discuss some limitations. First, we used a Pdgfrb-Cre that is active in the germline, which allowed us to ensure loss of mural cell insulin receptors during immediate postnatal vascular development; however, this means that cells expressing Pdgfrb during embryogenesis are likely to have undergone insulin receptor deletion. Although we saw no differences in whole retina or lung insulin receptor protein, nor developmental or growth defects, we cannot discount the
contribution of mural cell independent effects in vivo. However, our careful analysis of spatial Cre activity in the retina, analysis of isolated murine pericytes, and corroboration in human pericytes suggest that our pericyte observations are genuine. It is important to note that our analysis of Cre activity also indicates recombination in mural vascular smooth muscle cells lining arteries, which are very closely related to pericytes. Notably, published data have shown that insulin receptor knockout specifically in vascular smooth muscle cells protects against pathological intimal hyperplasia after arterial injury, supporting a broader role of insulin signaling in all vascular mural cells (52). Second, we have only explored developmental angiogenesis, and this may not be relevant to pathological states, so it will be important for future studies to explore this and also assess the vasculature of adult PIRKO mice, both in the quiescent state and during pathological angiogenesis. This will be important to define the wider relevance of pericyte insulin resistance to diabetic microvascular complications. Future studies should also explore extraretinal development during embryogenesis of PIRKO mice to understand the wider developmental implications. Next, while we observed robust mRNA knockdown of the insulin receptor in PIRKO pericytes, there was some residual (probably truncated) insulin receptor protein expression and we have not explored downstream insulin signaling pathways in pericytes to characterize residual signaling. Finally, although we explored the fundamental role of insulin receptors in murine and human pericytes, it is important not to assume these data describe the impact on pericyte insulin signaling in murine or human diabetes; indeed, diabetes induces insulin-signaling defects both at the receptor and multiple downstream nodes (8).

Conclusions

We provide the first ever in vivo assessment of mice with pericyte insulin receptor knockout and demonstrate impaired vascular quiescence and venous patterning during developmental retinal angiogenesis. We implicate diminished secretion of ANGPT1 by pericytes, resulting in impaired venous plexus endothelial cell Tie2 signaling to the transcription factor FoxO1, leading to augmented ANGPT2 expression. This vascular and molecular phenotype has clear parallels with diabetic retinopathy and future studies should explore the role of diminished pericyte insulin signaling in this disease.

Acknowledgments

We are grateful for support from the Faculty of Biological Sciences Bioimaging Facility, which has received equipment grants from the Wellcome Trust to purchase confocal microscopes used in this project. Y.A. was supported by a British Heart Foundation 4-year PhD fellowship (FS/17/66/33480). M.T.K. was supported by a British Heart Foundation chair.

Funding: N.W. was funded by a PhD fellowship from the University of Leeds Alumni Footsteps Fund. K.J.G. was funded by a British Heart Foundation Clinical Research Training Fellowship (FS/11/91/29090). R.M.C. was funded by a British Heart Foundation Intermediate Clinical Fellowship (FS/12/80/29821).

Author Contributions: N.W. conducted experiments, analyzed data, and wrote the manuscript. F.P., A.F.B., C.H.O., N.J.H., Y.A., C.S., V.P., P.S., N.Y.Y. conducted experiments, analyzed data, and edited the manuscript. S.B.W. acquired ethics approvals, supervised experiments, contributed to discussion, and reviewed and edited the manuscript. M.T.K. acquired funding, contributed to discussion, and reviewed and edited the manuscript. K.J.G. and R.M.C. designed study, acquired funding, conducted experiments, analyzed data, and wrote the manuscript.

Additional Information

Correspondence: Dr. Richard Cubbon, Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT laboratories, The University of Leeds, Clarendon Way, Leeds LS2 9JT, UK. Email r.cubbon@leeds.ac.uk; or Dr Kathryn Griffin, Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT laboratories, The University of Leeds, Clarendon Way, Leeds LS2 9JT, UK. k.j.griffin@leeds.ac.uk.

Disclosures: None.

Data Availability: All datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References

1. Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215.
2. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873-887.
3. Lindahl P, Johansson BR, Levén P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277(5323):242-245.
4. Møe MA, He L, Nordling S, et al. Single-cell analysis of blood-brain barrier response to pericyte loss. Circ Res. 2021;128(4):e46-e62.
5. Warmke N, Griffin KJ, Cubbon RM. Pericytes in diabetes-associated vascular disease. J Diabetes Complications. 2016;30(8):1643-1650.
6. Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in pre-diabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care. 2007;30(10):2708-2715.
7. Klein R, Myers CE, Lee KE, Gangnon R, Klein BE. Changes in retinal vessel diameter and incidence and progression of diabetic retinopathy. JAMA Ophthalmol. 2012;130(6):749-755.
8. Cubbon RM, Ali N, Sengupta A, Kearney MT. Insulin- and growth factor-resistance impairs vascular regeneration in diabetes mellitus. Curr Vasc Pharmacol. 2012;10(3):271-284.
9. Vanlandewijck M, He L, Møe MA, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554(7693):475-480.
10. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985;75(3):1028-1036.

11. Brüning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell. 1998;2(5):559-569.

12. Foo SS, Turner CJ, Adams S, et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell. 2006;124(1):161-173.

13. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45(9):593-605.

14. Pitulescu ME, Schmidt I, Benedito R, Adams RH. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat Protoc. 2010;5(9):1518-1534.

15. RRID:AB_11213678. http://antibodyregistry.org/AB_11213678.

16. RRID:AB_2082660. http://antibodyregistry.org/AB_2082660.

17. RRID:AB_2106495. http://antibodyregistry.org/AB_2106495.

18. RRID:AB_2083028. http://antibodyregistry.org/AB_2083028.

19. RRID:AB_884568. http://antibodyregistry.org/AB_884568.

20. RRID:AB_2536183. http://antibodyregistry.org/AB_2536183.

21. RRID:AB_2534104. http://antibodyregistry.org/AB_2534104.

22. RRID:AB_772206. http://antibodyregistry.org/AB_772206.

23. Daly C, Wong V, Burova E, et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 2004;18(9):1060-1071.

24. Chu M, Li T, Shen B, et al. Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFI. Elife. 2016;5:e21032.

25. Wilhem K, Happel K, Eelen G, et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature. 2016;529(7585):216-220.

26. Riddell M, Nakayama A, Hikita T, et al. aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability. Nat Commun. 2018;9(1):5357.

27. Ren B, Deng Y, Mukhopadhyay A, et al. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J Clin Invest. 2010;120(4):1217-1228.

28. Gaengel K, Genové G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29(5):630-638.

29. Pfister F, Wang Y, Schreiter K, et al. Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta Diabetol. 2010;47(1):59-64.

30. Park SW, Yun JH, Kim JH, Kim KW, Cho CH, Kim JH. Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes. 2014;63(9):3057-3068.

31. Teichert M, Milde L, Holm A, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:16106.

32. Park DY, Lee J, Kim J, et al. Plastic roles of pericytes in the blood-retinal barrier. Nat Commun. 2017;8:15296.

33. Walker AMN, Warnke N, Mercer B, et al. Endothelial insulin receptors promote VEGF-a signaling via ERK1/2 and sprouting angiogenesis. Endocrinology. 2021;162(8):bqab104.

34. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002;51(10):3107-3112.

35. Hammes HP, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53(4):1104-1110.

36. Tanii M, Yonemitsu Y, Fuji T, et al. Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res. 2006;98(1):55-62.

37. Hayden MR, Yang Y, Habibi J, Bagree SW, Sowers JR. Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes. Oxid Med Cell Longev. 2010;3(5):290-303.

38. Wong TY, Shankar A, Klein R, Klein BE. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes. Diabetes. 2004;53(1):179-184.

39. Tilton RG, Faller AM, Burkhardt JK, Hoffmann PL, Kilo C, Williamson JR. Pericyte degeneration and acellular capillaries are increased in the feet of human diabetic patients. Diabetologia. 1985;28(12):895-900.

40. Jeansson M, Gawlik A, Anderson G, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011;121(11):2705-2710.

41. Cahoon JM, Rai RR, Carroll LS, et al. Intravitreal AAV2.COMP- Ang1 prevents neurovascular degeneration in a murine model of diabetic retinopathy. Diabetes. 2015;64(12):4247-4259.

42. Li Q, Fu J, Xia Y, et al. Homozygous receptors for insulin and insulinlike growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res. 2006;98(1):55-62.

43. Park SW, Yun JH, Kim JH, Kim KW, Cho CH, Kim JH. Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes. 2014;63(9):3057-3068.

44. Teichert M, Milde L, Holm A, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:16106.

45. Park DY, Lee J, Kim J, et al. Plastic roles of pericytes in the blood-retinal barrier. Nat Commun. 2017;8:15296.

46. Walker AMN, Warnke N, Mercer B, et al. Endothelial insulin receptors promote VEGF-a signaling via ERK1/2 and sprouting angiogenesis. Endocrinology. 2021;162(8):bqab104.

47. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002;51(10):3107-3112.

48. Hammes HP, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53(4):1104-1110.

49. Tanii M, Yonemitsu Y, Fuji T, et al. Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res. 2006;98(1):55-62.